At a glance
- Brief doxycycline use in children does not stain teeth or weaken enamel.
- Doxycycline is the best treatment for Rocky Mountain spotted fever (RMSF), and other rickettsial infections.
- Treatment delays may lead to severe illness or death in some rickettsial diseases.
- Children are five times more likely than adults to die from RMSF.
Doxycycline and rickettsial diseases
Doxycycline is the most effective treatment of all rickettsial diseases including Rocky Mountain spotted fever, ehrlichiosis and anaplasmosis. It is the antibiotic recommended by the American Academy of Pediatrics (AAP) and CDC for the treatment of suspected rickettsial diseases in all patients. Studies have shown that other antibiotics are less effective and have a higher number of deaths (case fatality rate).
In a 2012 national survey, 80% of clinicians correctly selected doxycycline as the treatment of choice for suspected RMSF in persons over 8 years old. However, only 35% of clinicians correctly chose doxycycline as the treatment of choice for suspected RMSF in children under 8 years old. This hesitation may contribute to the increased fatality rate among children. Children under 10 years old represent less than 6% of RMSF cases, but they represent 22% of deaths. The same disproportionate case fatality rate in children has been observed for ehrlichiosis and other serious rickettsial infections.
Case Fatality Rate of Spotted Fever Rickettsiosis by Age Group, 2008 to 2013
Case Fatality Rate of Ehrlichia chaffeensis by Age Group, 2008 to 2013
Disease progression
Rickettsial diseases begin with non-specific symptoms, such as fever, headache, and gastrointestinal illness. A rash may develop around 2 to 5 days after the start of symptoms. This disease progresses rapidly into severe illness requiring hospitalization, or even death.
Rickettsia can lead to:
- Damage to the blood vessels leading to organ failure
- Amputation of extremities due to lack of blood flow
- Neurological deficits, like hearing loss, paralysis and encephalopathy
More than 20% of untreated cases of RMSF are fatal, with the median time from the beginning of symptoms to death being only 8 days.
Doxycycline is most effective when given within the first 5 days of illness. Because there is no rapid test to diagnose rickettsial diseases, clinicians must diagnose and treat based on clinical suspicion alone. It is important that concern about dental staining not cause providers to use other antibiotics or delay the start of treatment in children.
Evidence for lack of dental staining
Background
Tetracycline antibiotics are broad-spectrum antibiotics in use since the 1940s. Older tetracycline-class antibiotics have been linked to staining of permanent teeth and hypoplasia of dental enamel when used in children under 8 years old. In 1970, a warning label was attached to all tetracycline-class antibiotics advising against the use in children under 8 years old.
In 1967, doxycycline was introduced as a newer tetracycline-class antibiotic. Doxycycline binds less readily to calcium and has not been shown to cause the same tooth staining. Several studies have previously been published showing the lack of staining of permanent teeth when doxycycline was used in children. The warning, currently present on all tetracycline-class antibiotics, including doxycycline, continues to mention the concern regarding dental staining.
Purpose of dental staining study
In 2013, researchers from the CDC and IHS began looking into the possibility of dental staining following doxycycline usage, to better understand if this is an issue. This study was performed to look at whether or not doxycycline, in the dose and duration used to treat suspected RMSF, caused dental staining in children under 8 years old. The study took place in a community which has suffered from high rates of RMSF since 2003, where a large number of people, including children, were treated with doxycycline.
Study methods and results
Dentists inspected the permanent teeth of children who had received doxycycline for suspected RMSF prior to their 8th birthday and those who had not. Blinded dentists (without knowing which children had received the drug) looked for tooth staining, evaluated tooth color, and looked for evidence of weakness in the tooth enamel for all children in the study. No differences were found between children who had received doxycycline and those who had not.
Conclusion
This study provides the largest sample size and best evidence to date that short courses of doxycycline (such as those used to treat rickettsial diseases) do not cause dental staining when given to children under 8 years old.
The current label allows for the use of doxycycline in pediatric rickettsial patients because other antibiotics are not likely to be effective for treatment. However, clearer language on the drug label may help avoid hesitation in prescribing life-saving doxycycline to children and reinforce CDC and AAP RMSF treatment recommendations.
It is important for healthcare providers to know that doxycycline has not been shown to cause tooth staining in the dose and duration used to treat rickettsial diseases. Early administration of doxycycline in adults and children can prevent severe illness and death.
References
- "No Visible Dental Staining in Children Treated With Doxycycline for Suspected Rocky Mountain spotted fever."
- Doxycycline prescribing practices by clinicians for suspected RMSF
- Clinician knowledge, attitudes, and practices about RMSF in Tennessee
- Recommendations from the American Academy of Pediatrics
- Red Book: 2018 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2018
- Fatal Rocky Mountain spotted fever in the United States, 1999-2007
- Clinical Rocky Mountain spotted fever in children